What is HUTCHMED (China) Limited (HMDCF)?

HUTCHMED (China) Limited (HMDCF) is a stock in the Healthcare sector, Drug Manufacturers - Specialty & Generic industry. View full analysis on Stocks360.

What is the current price of HMDCF?

The current price of HMDCF is $2.16. Prices are updated in real time on Stocks360.

What is HMDCF's price-to-earnings (PE) ratio?

HMDCF's trailing twelve-month PE ratio is 142.89, based on current price and earnings per share data available on Stocks360.

What is HMDCF's market capitalization?

HMDCF's market capitalization is $1,877,193,012.00, placing it in the small-cap tier.

HUTCHMED (China) Limited (HMDCF)

Stock analysis · OTC · Healthcare · Drug Manufacturers - Specialty & Generic

$2.16

Market Cap

$1.88B

PE (TTM)

142.89

EPS (TTM)

N/A

Dividend Yield

0.00%

Beta

0.43

Day Range

$2.16 – $3.82

52-wk Range

$2.16 – $3.82

Avg Volume

N/A

Volume

468.00

HUTCHMED (China) Limited (HMDCF) is a publicly traded company in the Healthcare sector. Latest price: $2.16. Market cap $1.88B. Trailing PE 142.89. Sign in to Stocks360 for full DCF valuation, fundamentals, technicals, and AI-driven analysis.

Get full analysis → Short-Term Analysis →

1-Year Price

2025-10-30 · $3.66 2026-10-26 · $2.16 (-40.98%)

Earnings

Most Recent

Jul 30, 2026

EPS $0.02 vs est. $0.03

Missed by $0.01

Next Earnings

Mar 4, 2027

EPS estimate $0.04

Proprietary Signals

Signal snapshot temporarily unavailable.

About HUTCHMED (China) Limited

HUTCHMED (China) Ltd. operates as a holding company, specializing in the research, development, manufacturing, and sales of both pharmaceutical products and health-focused consumer goods. The company's operations are divided into two main segments: Oncology/Immunology and Other Ventures. The Oncology/Immunology division is dedicated to the discovery, development, and commercialization of targeted therapies and immunotherapies aimed at treating cancer and immunological diseases. In contrast, the Other Ventures segment handles the company's other commercial activities, which include the marketing, production, and distribution of prescription medications and general healthcare products. Established on December 18, 2000, the company maintains its headquarters in Hong Kong.

Valuation

Trailing twelve months. Multiples relative to current market price.
P/E (TTM)	142.89×
P/S (TTM)	4.18×
P/B	1.82×
P/FCF (TTM)	230.92×
EV / EBITDA	-111.40×
EV / Sales	4.16×
Earnings Yield	0.78%
Free Cash Flow Yield	0.43%

Fundamentals

Trailing twelve months. Source: financial statements via market data.
Enterprise Value	$2.29B
Revenue (TTM)	$549.12M
Net Income (TTM)	$17.95M
Free Cash Flow (TTM)	$9.95M
Net Debt	-$12.05M
Working Capital	$1.28B
Gross Margin	0.20%
Operating Margin	-6.33%
Net Margin	3.26%
Return on Equity	1.43%
Return on Invested Capital	-2.15%